Therapeutic cancer vaccines
761 views | +0 today
Your new post is loading...
Your new post is loading...
Scooped by Laurent LEVY
Scoop.it!

On-treatment immune analysis predicts response to melanoma immunotherapy

The leading news and search platform for precision medicine and medical diagnostics. From biomarkers to genetic testing and molecular diagnostics, a comprehensive review of up-to-date information required by researchers and physicians.
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

IO Landscape visualization - Beacon Intelligence

IO Landscape visualization - Beacon Intelligence | Therapeutic cancer vaccines | Scoop.it
Beacon Intelligence | Hanson Wade
Laurent LEVY's insight:
A spectacular visualization of the IO network • Currently there are 746 IO combination clinical trials (correct as of Aug 11th 2016) • These involve 47 different ICIs • 295 organizations are involved in these trials
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients

Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients | Therapeutic cancer vaccines | Scoop.it
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Merck, Moderna tie up in $200M deal to develop mRNA-based ‘personalized’ cancer vaccines | FierceBiotech

Merck, Moderna tie up in $200M deal to develop mRNA-based ‘personalized’ cancer vaccines | FierceBiotech | Therapeutic cancer vaccines | Scoop.it
Merck will pay $200 million upfront to Moderna, which the company will use to lead all R&D efforts through proof of concept and to build out a suburban Boston manufacturing facility. The program will focus on several types of cancer and include combinations with Merck’s Keytruda (pembrolizumab).
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Phase II Lung Cancer Clinical Trial Could Bring Another Immunotherapy Option to Mesothelioma Patients

Phase II Lung Cancer Clinical Trial Could Bring Another Immunotherapy Option to Mesothelioma Patients | Therapeutic cancer vaccines | Scoop.it
Using a special type of cell known as a dendritic cell that is a key regulator in the immune system, a U.S. company has created an immunotherapy treatment for lung cancer that is personalized to the patient’s specific tumor characteristics.
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Immune Evasion Pathways and the Design of Dendritic Cell-based Cancer Vaccines - Brent A Hanks - Discovery Medicine

Immune Evasion Pathways and the Design of Dendritic Cell-based Cancer Vaccines - Brent A Hanks - Discovery Medicine | Therapeutic cancer vaccines | Scoop.it
Emerging data is suggesting that the process of dendritic cell (DC) tolerization is an important step in tumorigenesis. Our understanding of the networks within the tumor microenvironment that functionally tolerize DC function is evolving while methods for genetically manipulating DC .
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Boehringer's VC fund leads Series A investment in cancer vaccine startup | FierceBiotech

Boehringer's VC fund leads Series A investment in cancer vaccine startup | FierceBiotech | Therapeutic cancer vaccines | Scoop.it
Boehringer Ingelheim Venture Fund has led a Series A investment intended to propel peptide-based cancer vaccine startup Amal Therapeutics toward clinical trials. The startup landed the investment on the strength of technology it thinks can address some of the historic failings of cancer vaccines.
Laurent LEVY's insight:
Share your insight
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

With $55M, Neon Wants To Make the Cancer Vaccine "Problem" Personal | Xconomy

With $55M, Neon Wants To Make the Cancer Vaccine "Problem" Personal | Xconomy | Therapeutic cancer vaccines | Scoop.it
One year ago, in a paper in the journal Oncoimmunology, three cancer researchers wrote this: "After many years of best efforts and countless dollars, but u
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Cancer Immunotherapy Market to Reach $9 Billion Across the World by 2022

Cancer Immunotherapy Market to Reach $9 Billion Across the World by 2022 | Therapeutic cancer vaccines | Scoop.it
PUNE, India, November 5, 2015 /PRNewswire/ -- Cancer Immunotherapy Market to Reach $9 Billion Across the World by 2022.
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Cancels Phase III Trials of Cancer Vaccine

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Cancels Phase III Trials of Cancer Vaccine | Therapeutic cancer vaccines | Scoop.it
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has contributed to medical science field in a number of ways over the last many years, but things have changed now. Reports claim that it has stopped Phase …
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Scientists Just Made a Breakthrough That Could Change the Face of Cancer Treatment

Scientists Just Made a Breakthrough That Could Change the Face of Cancer Treatment | Therapeutic cancer vaccines | Scoop.it
Scientists at the University College London (UCL) have made a major breakthrough that may further cement so-called immunotherapies' status as the most promising advance in cancer treatments in years. The researchers published their findings in the journal Science.
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Oncolytic viruses- A one of a kind FDA approval

Oncolytic viruses- A one of a kind FDA approval | Therapeutic cancer vaccines | Scoop.it
by Nishita Parnandi figures by Krissy Lyon One of the biggest challenges in treating cancer is to specifically target the cancerous site in a tissue without killing the surrounding normal cells. Th…
more...
No comment yet.
Rescooped by Laurent LEVY from Cancer Immunotherapy Review
Scoop.it!

Immuno-oncology | Novartis Institutes for BioMedical Research

Immuno-oncology | Novartis Institutes for BioMedical Research | Therapeutic cancer vaccines | Scoop.it

Immuno Oncology tumor antibodies - Image How can we treat patients so they become immune to their cancers?

 

One of our efforts is a landmark collaboration with the University of Pennsylvania on chimeric antigen receptor T (CAR-T) cell technology, which trains a patient’s own T cells to seek and destroy specific cancer cells. Our CAR-T cell treatments are in several Phase 2 clinical trials for cancers of the blood.

Another highly promising approach is “checkpoint inhibitor” drugs that can remove the brakes that cancer places on T cells. We have early clinical trials underway for inhibitors of PD-1 (programmed cell death protein 1), LAG-3 (lymphocyte activation gene 3), and other key molecular targets in certain solid tumors.  

We also are expanding our pipeline of potential immune therapies through collaborations. For instance, we work with Aduro Biotech to develop therapies that target the STING (stimulator of interferon genes) molecular pathway, which activates several signaling pathways that target disease. In animal models, agents that activate STING have completely eliminated certain tumors.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, February 15, 1:56 AM

Novartis is the leader in CAR-T cell therapy in early backing the research at UPenn.

Scooped by Laurent LEVY
Scoop.it!

Diagnostic Biomarkers for Cancer Immunotherapy – Moving Beyond PD-L1 / DeciBio | Insights

Diagnostic Biomarkers for Cancer Immunotherapy – Moving Beyond PD-L1 / DeciBio | Insights | Therapeutic cancer vaccines | Scoop.it
Decibio offers expert Mdx market reports, analysis of Life Sciences research tools market trends, NGS market growth reports, and DME market outlook reports.
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact | Xconomy

Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact | Xconomy | Therapeutic cancer vaccines | Scoop.it
Moderna Therapeutics still hasn’t produced data in humans supporting its technology, which is meant to turn our bodies into little drugmaking factories. Bu
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Caladrius Licenses Cell Therapy Technology to AiVita Biomedical | GEN News Highlights | GEN

Caladrius Licenses Cell Therapy Technology to AiVita Biomedical | GEN News Highlights | GEN | Therapeutic cancer vaccines | Scoop.it
Deal covering tumor cell/dendritic cell technology is second licensing agreement between the companies since February
Laurent LEVY's insight:
Caladrius—which changed its name last year from NeoStem—has also refocused its clinical development efforts on CLBS03, a Phase II T regulatory cell therapy candidate for type 1 diabetes
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy (NASDAQ:ARGS)

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy (NASDAQ:ARGS) | Therapeutic cancer vaccines | Scoop.it
DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (
Laurent LEVY's insight:
AGS-003 is an individualized immunotherapy designed to induce a memory T-cell response specific to each patient's cancer, including the unique tumor mutations (or neoantigens). It is produced using a small sample of RNA from a patient's own tumor, and dendritic cells derived from a cell collection procedure from the patient
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC

Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC | Therapeutic cancer vaccines | Scoop.it
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumou
Laurent LEVY's insight:
A total of 220 patients with metastatic NSCLC have now been enrolled in this Phase IIb trial across 70 European trial centres. The primary endpoint is to assess the benefit of Vx-001 versus placebo on overall survival. Final trial results are expected in the fourth quarter of 2016.
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

BMS' Opdivo gets two new indications in Europe - PMLiVE

BMS' Opdivo gets two new indications in Europe - PMLiVE | Therapeutic cancer vaccines | Scoop.it
Laurent LEVY's insight:
The new indication in non-small cell lung cancer (NSCLC) is for patients with squamous cell-derived tumours who have previously been treated for the disease with chemotherapy - adding to its existing second-line use in non-squamous NSCLC and for newly-diagnosed and previously-treated melanoma
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Principles and Application of Immunotherapy for Cancer: Advanced NSCLC

In this webcast from the 2015 CCO ACCC live meeting series on the Principles and Application of Immunotherapy for Cancer, Heather Wakelee, MD, provide
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Argos Nabs Up to $60M to Continue Kidney Cancer Treatment Work | Xconomy

Argos Nabs Up to $60M to Continue Kidney Cancer Treatment Work | Xconomy | Therapeutic cancer vaccines | Scoop.it
Argos Therapeutics reached an investment deal that provides up to $60 million in financing as the drug developer plows ahead on late-stage clinical trial w
more...
No comment yet.
Scooped by Laurent LEVY
Scoop.it!

Frontiers | Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines | Tumor Immunity

Frontiers | Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines | Tumor Immunity | Therapeutic cancer vaccines | Scoop.it
Cancer immunotherapy is currently the hottest topic in the oncology field, owing predominantly to the discovery of immune checkpoint blockers. These promising antibodies and their attractive combinatorial features have initiated the revival of other effective immunotherapies like dendritic cell (DC) vaccinations. Although DC-based immunotherapy can induce objective clinical and immunological responses in several tumor types, the immunogenic potential of this monotherapy is still considered suboptimal. Hence, focus should be directed on potentiating its immunogenicity by making step-by-step protocol innovations to obtain next-generation Th1-driving DC vaccines. We review some of the latest developments in the DC vaccination field, with a special emphasis on strategies that are applied to obtain a highly immunogenic tumor cell cargo to load and to activate the DCs. To this end, we discuss the effects of three immunogenic treatment modalities (ultraviolet light, oxidizing treatments and heat shock) and five potent inducers of immunogenic cell death (radiotherapy, shikonin, high-hydrostatic pressure, oncolytic viruses and (hypericin-based) photodynamic therapy) on DC biology and their application in DC-based immunotherapy in preclinical as well as clinical settings.
more...
No comment yet.